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Thymic size is increased by infancy, but not
pregnancy, nutritional supplementation in
rural Gambian children: a randomized
clinical trial
Sophie E. Moore1,2*, Anthony J. C. Fulford1, Fatou Sosseh1, Patrick Nshe1, Momodou K. Darboe1 and
Andrew M. Prentice1
Abstract
Background: Thymic size in early infancy predicts subsequent survival in low-income settings. The human thymus
develops from early gestation, is most active in early life and is highly sensitive to malnutrition. Our objective was
to test whether thymic size in infancy could be increased by maternal and/or infant nutritional supplementation.
Methods: The Early Nutrition and Immune Development (ENID) Trial was a randomized 2 × 2 × 2 factorial, partially
blinded trial of nutritional supplementation conducted in rural Gambia, West Africa. Pregnant women (N = 875)
were randomized to four intervention groups (iron-folate (standard care), multiple micronutrients, protein energy or
protein energy + multiple micronutrients at ‘booking’ (mean gestational age at enrolment = 13.6 weeks, range 8–20
weeks) until delivery. The iron-folate and multiple micronutrient arms were administered in tablet form and the
protein energy arms as a lipid-based nutritional supplement. All intervention arms contained 60 mg iron and 400 μg
folic acid per daily dose. From 24 to 52 weeks of age, infants from all groups were randomized to receive a daily
lipid-based nutritional supplement, with or without additional micronutrients. Thymic size was assessed by
ultrasonography at 1, 8, 24 and 52 weeks of infant age, and a volume-related thymic index calculated. Detailed data
on infant growth, feeding status and morbidity were collected.
Results: A total of 724 (82.7%) mother-infant pairs completed the trial to infant age 52 weeks. Thymic size in
infancy was not significantly associated with maternal supplement group at any post-natal time point. Infants who
received the daily LNS with additional micronutrients had a significantly larger thymic index at 52 weeks of age
(equivalent to an 8.0% increase in thymic index [95% CI 2.89, 13.4], P = 0.002). No interaction was observed between
maternal and infant supplement groups.
Conclusions: A micronutrient-fortified lipid-based supplement given in the latter half of infancy increased thymic
size, a key mediator of immune function. Improving the micronutrient status of infants from populations with
marginal micronutrient status may improve immune development and survival.
Trial registration: ISRCTN registry (controlled-trials.com) Identifier: ISRCTN49285450
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Background
Despite recent progress, infant and child mortality re-
mains at unacceptably high levels in low- and
middle-income countries (LMICs). Most deaths are
caused by infections and it has been estimated that mal-
nutrition contributes to 45% of all these deaths by limit-
ing immune competence [1]. Interventions to improve
nutritional status during pregnancy have been associated
with better birth outcomes, including neonatal survival
[2, 3] possibly through nutritionally mediated influences
on infant immune development.
In early childhood, the thymus is the main site for
clonal selection of lymphocytes and hence represents a
key organ orchestrating the development of adaptive im-
munity [4]. The thymus starts to develop very early in
gestation with fetal T cells detectable as early as 8 weeks.
It reaches its peak size in proportion to total body
weight very soon after birth and declines thereafter. Im-
portantly, thymic size assessed in early infancy has been
shown to predict subsequent survival in low-income set-
tings [5–7].
It has long been known that the thymus is exquisitely
sensitive to nutrition leading to it be described as a ‘bar-
ometer of malnutrition’ [8]. In mice, even short periods of
food restriction cause profound thymic atrophy and an as-
sociated reduction in T cell numbers mediated by de-
pressed leptin levels [9]. In humans, the thymic atrophy
caused by severe acute malnutrition can be rapidly re-
versed by appropriate nutritional rehabilitation [10, 11]
but there is no data linking thymic size and function with
the milder levels of malnutrition common in LMICs.
We conducted a proof-of-concept trial in rural Gambia
to test whether nutritional supplementation in early life
can enhance early immune development. The ENID (Early
Nutrition and Immune Development) trial was designed
to combine both pregnancy and infant interventions in
order to help determine the most efficacious form and
timing of nutritional support. Full details of the trial
protocol have been published previously [12]. We report
here the primary trial outcome, the impact of intervention
on infant thymic size across the first year of life.
Subjects and methods
Full details are provided in Additional file 1: Online Sup-
plementary Material and in the published trial protocol
[12]. In brief, see the following:
Study setting, participants and recruitment
The trial took place in the rural West Kiang region of
The Gambia. All women of reproductive age (18 to 45
years) registered within the West Kiang Demographic
Surveillance System [13] were invited to participate, and
informed consent obtained.
Participating women were visited monthly with a short
questionnaire on their last menstrual period. Height and
weight were measured at the first visit and weight
monthly thereafter. When a menses had been missed, a
urine sample was collected for pregnancy testing using
hCG kits. Women with positive results were invited for
an ultrasound examination. Those confirmed as < 20
weeks pregnant by ultrasound were randomized into the
trial with supplementation commencing the following
week. Exclusion criteria were gestational age ≥ 20 weeks,
multiple pregnancy, severe anaemia (haemoglobin (Hb)
< 7 g/dL) or confirmed as HIV positive.
Interventions: pregnancy
Women were randomized to one of four intervention
arms: (1) iron-folate (FeFol) tablets, representing the
usual standard of care as per Gambian Government
guidelines; (2) multiple micronutrient (MMN) tablets, a
combination of 15 micronutrients designed for use dur-
ing pregnancy as formulated by UNICEF/WHO/UNU
[14] (with the exception of iron and folate, each tablet
contained 2xRDA of each micronutrient [15]); (3) pro-
tein energy and iron-folate (PE+FeFol), as a lipid-based
nutritional supplement (LNS) providing the same level
of iron and folate as the FeFol arm, but with the addition
of energy, protein and lipids; and (4) protein energy and
multiple micronutrients (PE+MMN) as the same LNS
supplement fortified to provide the same level of micro-
nutrients as the MMN arm (including FeFol). The two
LNS (PE+FeFol and PE+MMN) provided an additional
746 kcal per day. The composition of the four supple-
ments is detailed in Additional file 1: Table S1.
Interventions: infancy
ENID trial participants were actively encouraged to ex-
clusively breastfeed their infants by community-based
health nurses. At 24 weeks of age, infants started supple-
mentation with either an unfortified LNS paste or the
same LNS formulation fortified with multiple micronu-
trients (Additional file 1: Table S2).
Randomization
Randomization was performed in blocks of 8, using an
automated system reflecting the 8 combinations of pre-
natal and infancy supplements. The antenatal arm of the
trial was partly open, since it was not possible to blind
project staff or study participants to the supplement type
(tablet versus LNS). The infant arm of the trial was
double blind, with infants receiving identically packaged
formulations.
Both antenatal and infant supplements were distrib-
uted on a weekly basis by a community-based field as-
sistant. Compliance was assessed through the collection
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of all unused supplements at the end of each week (tab-
let counts or empty/half-empty/full score for LNS).
Procedures
At booking, 20 and 30 weeks of gestation, women were
brought to the MRC Keneba clinic. At each visit, a
standard antenatal examination was performed by the
study midwives, with data collected on anthropometry,
blood pressure, Hb and urine analysis. Fasting venous
blood was collected (10 mL) and plasma and DNA
stored. At the 20 and 30 week visits, fetal biometry
(bi-parietal diameter, occipital frontal diameter, head cir-
cumference, abdominal circumference and femur and
tibia length) was measured by ultrasound.
Where possible, project staff attended deliveries to col-
lect and process cord blood and placenta samples [16].
Within 72 h of delivery, all women and their infants
were visited by a study midwife for a general health as-
sessment and a ‘baby check’ including infant anthropom-
etry (weight, length, head circumference and MUAC)
and gestational age assessment by Dubowitz score [17].
Infants were seen in Keneba when they were 1, 8, 12,
24 and 52 weeks of age and at home at 16, 20, 32 and
40 weeks. Thymus size was assessed sonographically at
1, 8, 24 and 52 weeks using a validated method in which
the transverse diameter and the sagittal area of its largest
lobe are multiplied together to give a volume-related
thymic index (TI) [18]. Data are expressed as cubic cen-
timetres but it should be noted that this is not the actual
volume. Ultrasound examinations were performed by
one observer (PN) to ensure consistency of measure-
ment. Infant anthropometry was recorded at all visits.
Any infant with a weight-for-length z-score < − 3SD
from the WHO reference was considered as having se-
vere acute malnutrition and withdrawn from the study
for admission and treatment at the MRC Keneba Nutri-
tional Rehabilitation Unit.
Data on maternal (during pregnancy only) and infant
(from birth to 52 weeks) morbidity were collected on a
weekly basis by questionnaire. At the weekly home visits,
a questionnaire on infant feeding practices was also
administered.
Sample analyses
Hb was measured in maternal whole blood samples
using a Medonic hemoglobinometer. Blood samples
were separated by centrifugation and plasma frozen at −
70 °C until analysis. Plasma folate was measured by
UPLC-MS/MS using an in-house assay based on a pub-
lished method [19].
Statistical analyses
Full details of the power calculations applied are pro-
vided in the published trial protocol [12]. To detect a 5%
difference in infant thymic size by intervention group,
with a power of 80% and at a significance level of 5%, we
estimated a required total sample size of 847
mother-infant pairs. Descriptive statistics for all variables
used in the analysis are presented by intervention arm.
Unadjusted between-arm differences were tested using
analysis of variance for continuous variables and
chi-squared tests for categorical variables. Infant anthro-
pometry was converted to Z-scores using the WHO
Child Growth Standards [20], and SGA was defined ac-
cording to a birth weight-for-gestational age < 10th per-
centile of the INTERGROWTH-21st standard [21]. Age
of weaning was defined as the age when the infant first
received weaning foods on two consecutive occasions.
Infant morbidity was coded as a pooled score of the
number of morbidity episodes. Episodes of diarrhoea
were additionally coded as a separate variable. However,
as this separation had little impact on the current ana-
lysis, we only present results using the pooled morbidity
variable.
Maternal compliance with the supplement was mea-
sured by dividing the number of tablets or jars of LNS
the mother consumed by the number offered, and infant
compliance by dividing the number of jars given by the
number of completed jars consumed, over the duration
of the intervention period.
Analyses of the main outcome data were performed
using either ordinary least squares regression or a ran-
dom effects model fitted by generalized least squares,
depending on whether each infant was represented by
one or more time points. The dependent variable was
the logarithm of TI. Since TI is strongly dependent on
both age and size of the infant, all models included
terms for infant length and its square, and, where the
full age range was analysed, orthogonal polynomials up
to degree four in infant age; otherwise, when a single
time point was analysed, a simple linear effect for age
was fitted. Terms to fit seasonality were used as previ-
ously described [22]. Results are presented according to
maternal intervention only, maternal and infant inter-
vention groups combined, and infant intervention only.
Results are presented as intention to treat analyses, but
analyses were also conducted using data on supplement
compliance. We present data on three models: Un-
adjusted and only including the two main maternal
intervention groups (PE and MMN); Model 1, adjusted
for modifying variables selected a priori for their known
association with thymic size in this environment [23]
(maternal size (BMI and height), infant age, infant
length, season of measurement) and (where relevant)
both maternal and infant compliance; and model 2 (for
analyses where infant age > 24 weeks) includes additional
post-natal variables, selected as potential mediators in
the association between supplement status and thymic
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size (infant feeding and morbidity). Effect sizes were cal-
culated by taking the exponential of the model coeffi-
cient and its CI limits. All analyses were run in Stata 12
(StataCorp LP, College Station, Texas).
Results
A total of 2798 women were enrolled for monthly sur-
veillance. Between January 2010 and June 2013, 1195
positive hCG tests were made, followed by an ultrasound
examination for pregnancy confirmation and dating. A
total of 875 (73.2%) of the women scanned were eligible
for enrolment and entered the antenatal supplementa-
tion phase of the trial (Fig. 1). Baseline characteristics of
the women, by supplement group, are detailed in Table 1.
Mean gestational age at enrolment into the trial was
13.6 weeks (range 7.0 to 20.8 weeks).
Women were enrolled in the antenatal supplementa-
tion phase of the trial for an average of 26.1 weeks (SD
= 4.4) and thus received nutritional supplements for this
period. Weeks of supplementation did not differ be-
tween groups (data not shown). Women who received
the tablet supplements (FeFol or MMN) had higher rates
of compliance (95.7% and 93.1%, respectively) than
women who received the LNS-based supplements (PE
+FeFol and PE+MMN, 81.7% and 81.2%; p value for the
difference between tablet and LNS groups < 0.0001).
Measured plasma total folate levels across pregnancy
support this higher supplement compliance among
tablet-based supplements: Plasma total folate levels in-
creased from baseline in both the FeFol and MMN
groups, but remained at similar levels to baseline in the
two LNS groups (data not presented).
A total of 75 women (8.6%) did not deliver a live born
infant into the trial (Fig. 1). Of the 800 live-born infants,
660 (83%) were seen within the first 72 h for a neonatal
examination including anthropometry. Mean (SD) birth-
weight was 3012 g (405), 9.6% of infants were born with
a low birth weight (< 2500 g) and 22% of infants were
born SGA. Additional file 1: Tables S3a and b detail in-
fant birth outcomes and infant anthropometry to 6 m by
antenatal supplement group and infant outcomes at 12
m by maternal and infant groups combined, and by in-
fant groups alone. As indicated, growth faltering was en-
demic within this population, with weight-for-age
z-scores (mean(SD)) declining from -0.68(0.90) to
-1.15(1.04) and height-for-age from -0.56(1.03) to
-0.99(1.04) over the first year of life. Exclusive breast-
feeding was common in early infancy within this popula-
tion, with a mean (SD) duration of exclusive
breastfeeding of 5.2(1.3) months, and with 31.4% of in-
fants exclusively breastfed to 6 months. Over the first
year of life, the mean incidence of morbidity episodes
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram showing participant flow in the trial. Abbreviations: FeFol, iron-folic acid;
MMN, multiple micronutrients; PE, protein energy; SAM, severe acute malnutrition. A miscarriage was defined using the WHO definition of the
premature loss of a fetus up to 23 weeks of pregnancy
Moore et al. BMC Medicine           (2019) 17:38 Page 4 of 9
(all reports summed) was 13.5 per infant, with 2.4 epi-
sodes of reported diarrhoea, 1.3 of vomiting, 4.0 of
cough, 0.3 of rapid breathing, 4.9 of fever and 3.2 of
‘other’ morbidity episodes.
Mean (SD) compliance to infant supplementation was
69.5(22.6)%. Infants randomized to the MMN fortified
LNS had a small but statistically significant lower mean
compliance compared to infants receiving the unfortified
LNS (68.3% vs 71.7%, p = 0.04). This did not differ by
maternal supplement group.
Mean thymic index (TI) and TI to weight ratio are re-
ported in Table 2. TI increased in absolute size from
birth to 24 weeks, decreasing again by 52 weeks. How-
ever, the TI to weight ratio was largest at the measures
taken in early infancy (week 1 and week 8) and smallest
at 1 year of age.
Maternal supplementation had no consistent impact
on infant TI, in either the unadjusted or adjusted models
(Table 3). A borderline negative effect of supplementa-
tion with PE during pregnancy on TI at week 1 was ob-
served, but this did not persist following adjustment for
co-variables. Supplementation with MMN to infants
from 24 to 52 weeks had a significant, positive impact on
infant TI; infants who received the LNS fortified with
MMNs had a significantly larger TI than those who
received the unfortified placebo LNS (Fig. 2; + 8.04%
(95% CI 2.89, 13.4), P = 0.002). This effect was observed
when both maternal and infant groups were fitted and in
both the adjusted models, with little evidence of medi-
ation by any of the selected co-variables (Table 3). There
was no significant interaction of the infant supplement
with maternal supplement (data not presented). Of note,
infant morbidity (sum of all morbidity episodes from 6
to 12 months of infant age) was significantly correlated
with TI at 12 months of age; a large TI was associated
with fewer morbidity episodes (< 0.0001; data not
presented).
Discussion
This randomized trial provides novel data suggesting
that direct supplementation to the infant from 24 to 52
weeks of age with MMNs provided in the form of a
small quantity LNS results in a modest but clear in-
crease in thymus size. Nutritional supplementation dur-
ing pregnancy conferred no benefit. These findings
support previous observational data suggesting the im-
portance of the early post-natal environment on thymus
size [23, 24] and specifically support a role for supple-
mentary micronutrients given in infancy. These findings
have implications beyond thymic development;
Table 1 Baseline characteristics of the women, by antenatal supplementation group
Maternal group FeFol MMN PE+FeFol PE+MMN
N 219 219 218 219
Maternal age (years) 29.3 (6.74) 30.4 (6.67) 29.0 (6.47) 29.9 (6.84)
Maternal education (years completed)a 1.34 (3.06) 2.03 (3.78) 1.52 (3.42) 1.31 (2.97)
Gestational age at booking (weeks) 13.8 (3.39) 13.7 (3.36) 13.6 (3.36) 13.4 (3.16)
Parity 4.30 (2.72) 3.81 (2.62) 3.95 (2.72) 4.34 (2.75)
Proportion of nulliparous women (%) 10.2 12.5 11.7 7.5
Weight (kg) 55.0 (9.0) 55.4 (9.83) 56.0 (9.29) 55.7 (10.7)
Height (cm) 161.6 (6.21) 162.1 (5.73) 161.9 (5.58) 161.6 (5.91)
BMI (kg/m2) 21.0 (3.23) 21.1 (3.76) 21.4 (3.30) 21.3 (3.59)
Proportion of women with BMI < 18.5 kg/m2 18.3 21.9 16.5 17.4
Proportion of women with BMI > 25 kg/m2 8.7 11.9 12.8 10.5
Haemoglobin (g/dL) 11.4 (1.40) 11.4 (1.33) 11.2 (1.39) 11.4 (1.33)
Proportion of women with haemoglobin < 11 g/dL 36.5 36.2 39.5 39.1
Abbreviations: FeFol iron-folic acid, MMN multiple micronutrients, PE protein energy, BMI body mass index
aMean of sum of years at Koranic or English Medium school
Table 2 Thymic index (TI) and TI to weight ratio by infant age
N Thymic index (cm3)a Thymic index to weight ratio (cm3/kg)
Week 1 765 9.18 (3.08) 2.78 (0.87)
Week 8 752 13.9 (4.09) 2.80 (0.76)
Week 24 747 14.7 (4.20) 2.13 (0.59)
Week 52 707 13.2 (3.71) 1.61 (0.45)
aMean (±standard deviation)
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improving the micronutrient status of infants from pop-
ulations with marginal status may improve immune de-
velopment and survival.
The thymus is the primary lymphoid organ essential
for the establishment of a normal peripheral T lympho-
cyte immune repertoire. However, the sonographic as-
sessment of TI used in the current trial represents an
anatomical rather than functional measure of infant im-
mune status. Limited published data exist to correlate TI
to immune function in infancy. In a small study of Da-
nish infants (N = 36 measured at 10 months of age), a
positive correlation was observed between TI and the
proportion of CD8+ cells in peripheral blood and the
CD4/CD8 ratio [25]. In a larger cohort study from The
Gambia (N = 138) however, no direct association was ob-
served between TI and lymphocyte subpopulations, al-
though a strong seasonal influence was observed on
both [26]. Notably, data from infants in Guinea-Bissau
and Bangladesh indicates that a small thymus in infancy
is an independent risk factor for infection-related mor-
tality in infancy [5–7], supporting the relevance of TI as
a predictor of future immunocompetence.
Existing literature suggests a beneficial effect of
post-natal nutrition on thymic development. Severe PE
malnutrition results in thymocyte death and thymic at-
rophy [27], and these effects appear to be reversible with
nutritional rehabilitation [11]. A limited number of stud-
ies in animal models have investigated the impact of
micronutrient deficiencies on thymic function (e.g. [28–
31]), but in humans, the focus has largely been on zinc.
Zinc plays a major role in cell division, differentiation,
apoptosis and gene transcription and strongly influences
the immune system, affecting primarily T cells [32], and
zinc supplementation in severely malnourished Jamaican
children was shown to increase radiographically assessed
thymic size [10]. Ours is the first published trial to dem-
onstrate a positive effect on thymic size through supple-
mentation with multiple micronutrients. The
supplement included 22 micronutrients, and so under-
standing the mechanism of effect is difficult. Of note,
children who received the MMN fortified LNS were not
significantly bigger at 52 weeks of age than those chil-
dren who received the placebo supplement, and the ef-
fect on TI persisted when adjusted for infant size.
Supplemented children had a non-significantly lower in-
cidence of morbidity than the control children and chil-
dren with a larger TI at 12 months of age had
significantly fewer morbidity episodes during the time of
supplementation from 6 to 12months of age; however,
understanding causality in this context is not possible.
We did not observe a consistent effect of any of the
antenatal supplement groups on infant thymic size, as
compared to the usual standard of care (daily iron and
folic acid only). This result was surprising, as the supple-
ments were purposefully designed to ensure nutritional
repletion in this context. The additional micronutrients
provided in the MMN and PE+MMN arms contained
twice the RDA for pregnancy, with the exception of iron
and folic acid which were kept consistent across all
groups, in line with Gambian Government guidelines.
The two LNS arms (PE+FeFol and PE+MMN) were for-
mulated as a large quantity LNS, containing 746 kcal per
daily dose. This is considerably higher than the standard
Table 3 Effect of pregnancy and infancy nutritional
supplementation on infant thymic index
Effect size (%)a 95% CI P value
Week 1 only
Unadjusted
PE − 5.03 − 9.75, − 0.05 0.05
MMN 2.16 − 2.91, 7.52 0.41
Model 1b
PE − 3.49 − 8.23,1.49 0.17
MMN 1.68 − 3.28, 6.93 0.51
All time points to infant age < 6 months
Unadjusted
PE − 2.07 − 5.14, 1.12 0.20
MMN 1.71 − 1.49, 5.01 0.30
Model 1
PE − 0.89 − 3.85, 2.16 0.56
MMN 2.10 − 0.95, 5.24 0.18
Combined maternal and infant—week 52 only
Unadjusted
PE − 2.19 − 6.84, 2.71 0.38
MMN 2.13 − 2.72, 7.25 0.39
Infant MMN 8.08 2.92, 13.48 0.002
Model 1
PE − 1.97 − 6.64, 2.92 0.42
MMN 2.31 − 2.56, 7.43 0.36
Infant MMN 8.50 3.28, 13.97 0.001
Model 2c
PE − 1.91 − 6.56, 2.97 0.44
MMN 2.06 − 2.79, 7.14 0.41
Infant MMN 7.99 2.81, 13.43 0.002
Infant supplement only
Unadjusted 8.04 2.89, 13.44 0.002
Model 1 8.80 3.20, 13.81 0.001
Model 2 8.10 2.92, 13.55 0.002
Abbreviations: PE protein energy, MMN multiple micronutrients
aEffect size computed as 100 × [antilog(β) − 1] where β is the regression
coefficient from regression models
bModel 1 adjusted for infant size, infant age, infant sex, season of
measurement and maternal size (BMI and height) and (as relevant) maternal
and infant compliance to supplement
cModel 2 (for data up to week 52 only) adjusted for the same variables as
model 1, but also infant age at weaning (defined as the age of introduction of
non-breast milk feeds) and infant morbidity (sum of morbidity episodes across
the first year of life)
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118 kcal per day used in the more typically given small
quantity LNS preparations.
Our data indicate that compliance with the pregnancy
LNS supplement was poor, as compared to tablets, pos-
sibly impacting the results observed. The PE supplement
was administered in a daily dose, providing 746 kcal/day,
with women encouraged to consume the entire dose
herself, either directly from the pot or mixed with other
foods. Both self-reported compliance and the available
data on plasma total folate levels (data not presented
here) indicate that not all women adhered to the proto-
col. A small qualitative study embedded within the
ENID Trial focused on understanding maternal percep-
tions to the supplements (tablets vs LNS supplement
groups) and highlighted a number of reported concerns
(e.g. poor acceptability of the smell and taste of the LNS,
side effects of nausea and vomiting), possibly contribut-
ing to poor compliance [DalyA, Understanding the
differential effects and perceptions of lipid-based nutrient
supplements compared with tablet supplements on the
habitual dietary intake and behaviours of pregnant women
in rural Gambia, MSc Dissertation: London School of
Hygiene and Tropical Medicine, unpublished]. Supple-
ment sharing among family members, however, was not
reported. A small number of other published studies, from
a variety of settings, have reported acceptability and com-
pliance data from trials of LNS given in pregnancy and
lactation. In trials using small quantity LNS products (typ-
ically 20 g, providing 118 kcal per day) in Ghana [33, 34],
Malawi [34] and Bangladesh [35], no differences were ob-
served between the LNS products and comparison groups
(iron-folic acid or multiple micronutrient tablets), despite
participants reporting a number of acceptability issues
largely related to associated side effects (vomiting, nausea,
etc.). A single study using a higher dose LNS (372 kcal/d)
in pregnant women in Burkina Faso also found no statis-
tical difference in compliance between the LNS and mul-
tiple micronutrient arms [36]. The findings of a lower
compliance with the much higher dose LNS given in our
trial cautions against the suitability of using such products
during pregnancy.
To the best of our knowledge, this is the first pub-
lished trial to look at the impact of combined maternal
and infant nutritional supplementation on infant im-
mune development, and in a population with high rates
of maternal and infant undernutrition. The further
strengths of the study include the individual random as-
signment, early detection of pregnancy complete with
ultrasound dating, high retention rates, and the detailed,
longitudinal assessment of the primary trial outcome,
thymic index. The number of participants recruited (875
mother-infant pairs) was consistent with the a priori
sample size calculation [12], providing sufficient power
to test the primary hypothesis of effect by both maternal
and infant supplement group. The primary limitation
was the poorer compliance to the antenatal LNS arms of
the trial and low compliance with the infant supplement.
Supervised supplementation may have avoided this issue.
Conclusion
In conclusion, we have shown that infant thymic size is
increased in rural Gambian infants supplemented with
small quantity LNS containing multiple micronutrients.
No effect was observed with either PE, MMN or com-
bined PE and MMN supplementation when given to the
mother during pregnancy, and there was no apparent
Fig. 2 Impact of infant micronutrient supplementation on thymic index at 52 weeks of age. Percent (standard error) difference in mean thymic
index between successive time points
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interaction between antenatal and infant administered
MMN supplementation. Because the effect on TI was in-
dependent of an effect on infant size, we conclude a dir-
ect benefit on infant thymic size of MMN administered
during infancy. The immunomodulatory consequences
of this increase in thymus size, and the longevity of the
effect, require further investigation.
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